mitomycin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, nucleotoxic agents 1819 50-07-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mitomycin
  • mutamycin
  • Mitomycin C
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
  • Molecular weight: 334.33
  • Formula: C15H18N4O5
  • CLOGP: -1.35
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 146.89
  • ALOGS: -1.52
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 24, 1981 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 106.05 31.94 101 1798 379740 46304423
Scleral thinning 105.60 31.94 13 1886 22 46684141
Conjunctival filtering bleb leak 95.45 31.94 11 1888 6 46684157
Haemolytic uraemic syndrome 80.47 31.94 19 1880 2495 46681668
Pulmonary veno-occlusive disease 74.98 31.94 15 1884 906 46683257
Conjunctival erosion 66.87 31.94 8 1891 9 46684154
Mucosal inflammation 57.07 31.94 29 1870 38947 46645216
Malignant neoplasm progression 55.78 31.94 34 1865 64892 46619271
Leukopenia 49.19 31.94 32 1867 68311 46615852
Neutropenia 49.15 31.94 43 1856 143161 46541002
Thrombocytopenia 47.48 31.94 40 1859 126541 46557622
Bladder perforation 42.48 31.94 7 1892 140 46684023
Hypotony of eye 42.43 31.94 7 1892 141 46684022
Necrotising scleritis 41.34 31.94 7 1892 166 46683997
Iris transillumination defect 41.06 31.94 6 1893 52 46684111
Metastases to liver 38.99 31.94 18 1881 19567 46664596
Extravasation 37.67 31.94 10 1889 2105 46682058
Eye infection toxoplasmal 37.54 31.94 7 1892 291 46683872
Disease progression 36.57 31.94 30 1869 91270 46592893
Limbal stem cell deficiency 33.67 31.94 4 1895 4 46684159
Tractional retinal detachment 33.57 31.94 5 1894 50 46684113

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 146.07 30.07 111 1408 249179 29701780
Conjunctival filtering bleb leak 84.23 30.07 10 1509 6 29950953
Scleral thinning 84.23 30.07 10 1509 6 29950953
Bladder perforation 83.52 30.07 14 1505 248 29950711
Iris hypopigmentation 51.60 30.07 7 1512 25 29950934
Conjunctival erosion 48.71 30.07 6 1513 7 29950952
Bladder necrosis 44.46 30.07 5 1514 0 29950959
Scrotal ulcer 40.90 30.07 8 1511 343 29950616
Gastric perforation 40.26 30.07 11 1508 2070 29948889
Post embolisation syndrome 38.70 30.07 6 1513 63 29950896
Eosinophilic cystitis 35.50 30.07 5 1514 25 29950934
Hypotony of eye 34.67 30.07 6 1513 129 29950830
Extravasation 32.30 30.07 9 1510 1819 29949140
Conjunctival bleb 31.90 30.07 4 1515 6 29950953

Pharmacologic Action:

SourceCodeDescription
ATC L01DC03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Other cytotoxic antibiotics
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug
MeSH PA D000477 Alkylating Agents
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
MeSH PA D003432 Cross-Linking Reagents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D007202 Indicators and Reagents
MeSH PA D009676 Noxae
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
CHEBI has role CHEBI:35610 cytostatic

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Adenocarcinoma of pancreas indication 700423003 DOID:4074
Metastatic Gastric Cancer indication
Non-small cell lung cancer off-label use 254637007 DOID:3908
Malignant tumor of head and/or neck off-label use 255056009
Malignant tumor of anus off-label use 363490009 DOID:14110
Malignant tumor of urinary bladder off-label use 399326009 DOID:11054
Prevention of Recurrent Bladder Carcinoma off-label use
Corneal Conjunctival Intraepithelial Neoplasm off-label use
Stomatitis contraindication 61170000 DOID:9637
Acute infectious disease contraindication 63171007
Blood coagulation disorder contraindication 64779008 DOID:1247
Heart failure contraindication 84114007 DOID:6000
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Hemolytic uremic syndrome contraindication 111407006 DOID:12554
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Pulmonary Infiltrates contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.54 acidic
pKa2 10.39 Basic
pKa3 7.53 Basic
pKa4 4.95 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
40MG/VIAL JELMYTO UROGEN PHARMA N211728 April 15, 2020 RX POWDER PYELOCALYCEAL April 15, 2023 NEW PRODUCT
40MG/VIAL JELMYTO UROGEN PHARMA N211728 April 15, 2020 RX POWDER PYELOCALYCEAL April 15, 2027 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Indoleamine 2,3-dioxygenase 1 Enzyme Ki 4.60 CHEMBL
DNA DNA OTHER DRUG LABEL DRUG LABEL

External reference:

IDSource
4018134 VUID
N0000146471 NUI
D00208 KEGG_DRUG
4018134 VANDF
C0002475 UMLSCUI
CHEBI:27504 CHEBI
CHEMBL105 ChEMBL_ID
D016685 MESH_DESCRIPTOR_UI
DB00305 DRUGBANK_ID
7089 IUPHAR_LIGAND_ID
3043 INN_ID
50SG953SK6 UNII
5746 PUBCHEM_CID
204298 RXNORM
1274 MMSL
1973 MMSL
5122 MMSL
d00305 MMSL
002660 NDDF
387331000 SNOMEDCT_US
59240002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9279 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 17 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9280 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 17 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-108 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-115 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-116 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-246 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-247 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-248 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-518 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-519 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-520 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-995 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-996 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-997 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 68001-389 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 68001-390 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 68001-391 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections
MUTAMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 69448-001 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
MUTAMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 69448-002 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
MUTAMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 69448-003 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections